Taysha Gene Therapies, Inc. (TSHA)
$0.7596
Rating:
Recommendation:
-
| Symbol | TSHA |
|---|---|
| Price | $0.7596 |
| Beta | 1.222 |
| Volume Avg. | 0.55M |
| Market Cap | 53.302M |
| Shares () | - |
| 52 Week Range | 0.6806-7.077 |
| 1y Target Est | - |
| DCF Unlevered | TSHA DCF -> | |
|---|---|---|
| DCF Levered | TSHA LDCF -> | |
| ROE | -338.37% | Strong Sell |
| ROA | -144.15% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 901.87% | Strong Buy |
| P/E | -0.25 | Neutral |
| P/B | 2.79 | Strong Buy |
Latest TSHA news
About
Download (Excel)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.